ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
A key pivotal study of bemarituzumab will read out shortly.
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
US approval could mark the company's graduation to oncology.
The FDA will rule on a low dose of zongertinib in the summer.
A triplet did worse than control in first-line kidney cancer.
Meanwhile, Tango tries again in PRMT5.
